Advertisement

PharmacoEconomics

, Volume 36, Issue 11, pp 1367–1376 | Cite as

Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case–Control Study in Japan

  • Haruhisa Fukuda
  • Takahisa Yano
  • Nobuyuki Shimono
Original Research Article

Abstract

Background

Hospital-onset Clostridium difficile infections (CDIs) have a considerable clinical and economic impact on patients and payers. Quantifying the economic impact of CDIs can guide treatment strategies. However, previous studies have generally focused on acute care hospitals, and few have included cost estimates from non-acute care hospitals such as long-term care facilities.

Aim

This study aimed to quantify the hospital-onset CDI-attributable inpatient expenditures and length-of-stay durations in all healthcare institutions that provide inpatient care (including acute and non-acute care) in Japan.

Methods

Using national-level insurance claims data, we analyzed patients who had been hospitalized between April 2010 and December 2016. CDI cases were identified and matched with non-CDI controls using hospitalization year, treating hospital, age, sex, surgical procedure, comorbidities, and main diagnoses. Through multivariable regression analyses, we estimated the CDI-attributable inpatient expenditures (2016 US dollars) and length-of-stay durations (days) while adjusting for variations in factors such as patient characteristics, comorbidities, surgery, prescribed antibiotic, geographic region, and hospitalization year. We also analyzed the CDI-attributable inpatient expenditures and length-of-stay durations according to hospital type (acute care and rehabilitation/long-term care).

Results

The analysis was conducted using 3768 matched pairs. Overall, CDI-attributable inpatient expenditures and length-of-stay durations were US$3213 and 11.96 days, respectively. Rehabilitation/long-term care hospitals had substantially higher inpatient expenditures and longer hospitalizations than acute care hospitals.

Conclusion

This study quantified the hospital-onset CDI-attributable inpatient expenditures and hospitalizations in both acute and non-acute care hospitals. The inclusion of non-acute care hospitals provides a more accurate representation of the economic burden of CDIs.

Notes

Acknowledgements

We are grateful to Mr S. Kondo and Mr S. Yamakawa from Denno Labo Corporation for their support in extracting the study sample from the National Database (NDB).

Author Contributions

Haruhisa Fukuda, Takahisa Yano, and Nobuyuki Shimono contributed to the study’s conception and design. Haruhisa Fukuda carried out the analysis of the data and drafted the manuscript. All authors were involved in the interpretation of the results, as well as in the editing and revision of the manuscript.

Compliance with Ethical Standards

Source of Funding

This work was supported by a Grant-in-Aid for Health Sciences Research by the Ministry of Health, Labor and Welfare of Japan (Grant Number: H29-Seisaku-Shitei-010) and a KAKENHI Grant-in-Aid for Scientific Research by the Japan Society for the Promotion of Science (Grant Number: JP17H04144).

Conflict of Interest

Haruhisa Fukuda, Takahisa Yano, and Nobuyuki Shimono declare that they have no conflicts of interest, financial or otherwise.

References

  1. 1.
    Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73.CrossRefGoogle Scholar
  2. 2.
    Honda H, Dubberke E, Fukuda T, Senoh M, Reske K, Olsen M, et al. Epidemiology of Clostridium difficile infections in Japan. IDWeek 2016; New Orleans October 26–30.Google Scholar
  3. 3.
    Kim JH, Toy D, Muder RR. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol. 2011;32(7):656–60.CrossRefGoogle Scholar
  4. 4.
    Campbell RJ, Giljahn L, Machesky K, Cibulskas-White K, Lane LM, Porter K, et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol. 2009;30(6):526–33.CrossRefGoogle Scholar
  5. 5.
    Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. BMC Geriatr. 2016;16(1):193.CrossRefGoogle Scholar
  6. 6.
    Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol. 2013;34(6):588–96.CrossRefGoogle Scholar
  7. 7.
    Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29(9):823–8.  https://doi.org/10.1086/588756.CrossRefPubMedGoogle Scholar
  8. 8.
    Stevens VW, Khader K, Nelson RE, Jones M, Rubin MA, Brown KA. Excess length of stay attributable to clostridium difficile infection (CDI) in the acute care setting: a multistate model. Infect Control Hosp Epidemiol. 2015;36(9):1024–30.CrossRefGoogle Scholar
  9. 9.
    Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–53.CrossRefGoogle Scholar
  10. 10.
    Magee G, Strauss ME, Thomas SM, Brown H, Baumer D, Broderick KC. Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: a multicenter retrospective study of inpatients, 2009-2011. Am J Infect Control. 2015;43(11):1148–53.CrossRefGoogle Scholar
  11. 11.
    Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect. 2008;70(1):15–20.CrossRefGoogle Scholar
  12. 12.
    Asensio A, Di Bella S, Lo Vecchio A, Grau S, Hart WM, Isidoro B, et al. The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. Int J Infect Dis. 2015;36:31–8.CrossRefGoogle Scholar
  13. 13.
    Heimann SM, Vehreschild JJ, Cornely OA, Wisplinghoff H, Hallek M, Goldbrunner R, et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015;43(6):707–14.CrossRefGoogle Scholar
  14. 14.
    Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. The burden of Clostridium difficile-associated disease following digestive tract surgery in Japan. J Hosp Infect. 2012;82(3):175–80.CrossRefGoogle Scholar
  15. 15.
    Burton HE, Mitchell SA, Watt M. A Systematic literature review of economic evaluations of antibiotic treatments for clostridium difficile infection. Pharmacoeconomics. 2017;35(11):1123–40.CrossRefGoogle Scholar
  16. 16.
    Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefGoogle Scholar
  17. 17.
    McDonald LCL, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28(2):140–5.CrossRefGoogle Scholar
  18. 18.
    Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.CrossRefGoogle Scholar
  19. 19.
    van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–33.CrossRefGoogle Scholar
  20. 20.
    Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12:308–31.Google Scholar
  21. 21.
    Mitchell BG, Gardner A, Barnett AG, Hiller JE, Graves N. The prolongation of length of stay because of Clostridium difficile infection. Am J Infect Control. 2014;42(2):164–7.CrossRefGoogle Scholar
  22. 22.
    van Kleef E, Green N, Goldenberg SD, Robotham JV, Cookson B, Jit M, et al. Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach. J Hosp Infect. 2014;88(4):213–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Health Care Administration and ManagementKyushu University Graduate School of Medical SciencesFukuokaJapan
  2. 2.Center for the Study of Global InfectionKyushu University HospitalFukuokaJapan

Personalised recommendations